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Abstract
Chronic obstructive pulmonary disease (COPD) is a lung disorder that is 
triggered by permanent, irreversible obstruction of airflow and an abnormal 
inflammatory response. COPD places a huge burden on both the patient and the 
healthcare system. Several studies now exist that link COPD to vitamin D 
deficiency. It is thought that lower serum concentrations of vitamin D can cause a 
reduction in lung function due to its role in the innate and adaptive immune 
responses. This meta-analysis evaluates whether or not the use of supplemental 
vitamin D (I) in individuals diagnosed with COPD who have a clinical vitamin D 
deficiency (P), provides improved symptomatic relief (O) compared to the use of 
standard therapy alone (C).
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Chronic Obstructive Pulmonary Disease (COPD)
Overview
➢ Consists of emphysema and chronic bronchitis
➢ Irreversible obstruction of airflow and abnormal inflammatory response in the lungs
➢ Almost exclusively caused by cigarette smoking in developed countries
➢ Affects > 16 million Americans
Signs and Symptoms
➢ Shortness of breath
➢ Emphysema: pursed-lip breathing, hyperinflation
➢ Chronic bronchitis: productive cough, prolonged expiration
Diagnosis
➢ FEV1/FVC ratio < 0.7 post-bronchodilation
➢ FEV1 = forced expiratory volume in one second and FVC = forced vital capacity 
Treatment
➢ First line treatments: smoking cessation, short- and long-acting anticholinergics, 
bronchodilators, corticosteroids
➢ Connection between COPD and vitamin D deficiency leaves hope that vitamin D 
supplementation may reduce the number of acute exacerbations, provide symptomatic 
relief, and improve overall quality of life in COPD patients
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Literature Search
➢Performed in April 2019 using:
✓Academic Search Ultimate
✓ PubMed
✓Google Scholar
➢ Search Terms: “COPD AND vitamin D 
deficiency AND treatment”
➢ Inclusion Criteria:
1. Published in peer-reviewed journal
2. Published 2009 or later
3. Written in English
4. Adult human subjects
➢ Exclusion Criteria:
1. Systematic reviews or meta-
analyses
2. Clinical trials involving animals
4/6 studies found some efficacy in the use of vitamin D 
supplementation in patients with COPD and concomitant 
vitamin D deficiency
Strengths
➢5/6 studies were RCT → excludes bias
➢Explicit documentation of statistical analysis with p < 0.05 
being considered statistically significant
➢No study reported negative side-effects of vitamin D 
supplementation
Limitations
➢Small sample sizes
➢Brief timeline
➢Lack of target vitamin D
Future Research
➢What is the optimal serum vitamin D level to provide 
clinically significant improvement in symptomatic COPD 
patients?
➢Larger sample sizes
➢Long-term follow-up
Discussion Results 
The efficacy of Vitamin D as adjunctive treatment
of Chronic Obstructive Pulmonary Disease
While the question remains as to whether vitamin D 
supplementation will become common practice in the adjunctive 
treatment of COPD, it can be concluded that some promising 
research exists regarding its efficacy. Despite the limitations of the 
trials discussed, there were some positive findings to indicate 
improved quality of life and pulmonary function in select patients. 
Vitamin D is an inexpensive and innocuous supplement that can 
easily be incorporated into the treatment of COPD. Although the 
results of these studies alone do not justify the use of vitamin D in 
all patients with COPD, it does provide some evidence to the 
importance of its role in patients with a vitamin D deficiency.
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a placebo group
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of life in hospitalized patients with “acute exacerbation of Chronic Obstructive Pulmonary Disease.” 
Iranian Journal of Pharmaceutical Research. 2018;17(2):801-810
➢ RCT of 62 participants designed to test the efficacy of receiving a single dose of IM vitamin D3 
(300,000 IU) as adjunctive treatment for COPD during acute exacerbation as compared to the 
placebo
5. Rafiq R, Prins HJ, Boersma WG, et al. Effects of daily vitamin D supplementation on respiratory muscle 
strength and physical performance in vitamin D-deficient COPD patients: a pilot trial. International 
Journal of Chronic Obstructive Pulmonary Disease. 2017;12(1):2583-2592
➢ RCT of 43 participants designed to test the efficacy of daily vitamin D supplementation (1200 
IU) as adjunctive treatment in patients with COPD as compared to the placebo
6. Sanjari M, Soltani A, Khorasani AH, et al. The effect of Vitamin D on COPD exacerbation: a double 
blind randomized placebo-controlled clinical trial. Journal of Diabetes & Metabolic Disorders. 
2016;15(33):257-264
➢ RCT of 120 participants designed to test the efficacy of 50000 IU vitamin D3 x 7d vs 0.25 μg 
vitamin D (calcitrol) x 7d vs placebo as adjunctive treatment of COPD during an acute 
exacerbation
Study
Population 
Demographics
Disease at 
Baseline
Control Tx Regimen Outcome Measure(s)
1
Age 18-65 yo
From south 
India
Unknown --- --- Serum 25-OHD
2
Current or 
former smoker
Age > 50 yo
GOLD COPD dx
FEV1 < 80% 
predicted value
Placebo (4 ml 
arachidis
oleum) 
Vit D (100,000 IU 
cholecalciferol)
Serum 25-OHD
Spirometry: FEV1, FVC
MIP and MEP (Black and Hyatt method)
Functional exercise capacity
Maximal exercise capacity (ergometer)
CRDQ – health related quality of life
3
Age 18-60 yo
Normal BMI
1.8M:1F
FEV1 < 80% 
predicted value
No Vitamin D
Vitamin D 2000 
IU PO daily
Serum 25-OHD
Spirometry: FEV1, FVC
4
Age > 40 yo
Current acute 
exacerbation 
admitted from 
ED
GOLD stage II-IV, 
FEV1 < 80% 
predicted value
Placebo
Vit D
(300,000 IU IM 
cholecalciferol)
Serum 25-OHD
SGRQ (HRQOL)
mMRC scale (dyspnea severity)
Length of hospital stay
Mortality rates
5
Age 40-70 yo
Vit D deficiency: 
serum 25-OHD 
< 50 nmol/L
FEV1 < 80% 
predicted value
Placebo
Vitamin D3 1,200 
IU PO daily 
(cholecalciferol)
MIP and MEP
Functional exercise capacity
Spirometry: FEV1, FVC
Handgrip strength
Serum 25-OHD
6
Age 40-60 yo
Ex-smoker
Acute 
exacerbation of 
COPD admitted 
from ED
FEV1 < 88% for 
males and < 89% 
for females
Placebo (group 
A)
50000 IU vitamin 
D PO daily (group 
B)
0.25 μg calcitriol 
PO daily (group 
C)
Spirometry: FEV1, FVC
mMRC
Key: CRQD = chronic respiratory distress questionnaire, SGRQ = St. George’s respiratory questionnaire, HRQOL = health related quality of life questionnaire, mMRC = 
modified medical research council, MIP = maximal inspiratory pressure, MEP = maximal expiratory pressure
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